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Abstract
The use of immunotherapies is gaining importance in the treatment of advanced 
malignancies. There are many checkpoints in the immune system which prevents 
T-cells from attacking one’s own body cells. The cancer cells can camouflage from the 
T-cells and the immune system is unable to mount an effective anti-tumor response. 
The immunotherapies, mainly monoclonal antibodies anti-cytotoxic T-lymphocyte 
antigen 4 (CTLA-4), anti-programmed cell death protein-1 (PD-1) and anti-PD-1 
ligand molecules (PD-L1 and L2) reactivate the immune system to act against cancer-
ous cells but they can also cause T-cells to attack healthy cells causing various autoim-
mune diseases, which are known as immune related adverse events (irAEs). Current 
clinical data shows increased incidence of pituitary disorders with CTLA4 inhibitors 
and thyroid dysfunction in patients with PD-1/PD L-1 1 blockade. There have also 
been association of type 1 diabetes mellitus and primary adrenal insufficiency in 
patients with immune check point inhibitors. In this chapter we will discuss the inci-
dence, characteristic findings, diagnosis and management of various endocrinological 
side effects due to targeted immunotherapies used in various malignancies.
Keywords: cancer immunotherapy, immune check point inhibitors, endocrine side 
effects, thyroid dysfunction, hypophysitis, primary adrenal insufficiency, Type 1 
diabetes mellitus
1. Introduction
Immune system detects and destroys abnormal cells through immune surveillance 
and as a part of this prevents growth of many impending cancers. Immunotherapies 
work by either activating or suppressing the immune system and have emerged as 
important part of how we treat different types of cancers in last few decades [1].
Immune inhibitor pathway plays an important role in maintenance of self-
tolerance, and cancer cells evade immune mediated destruction by upregulation 
of immune inhibitory pathways. Immunotherapy can be used to suppress these 
immune checkpoints resulting in antitumor activity. Immune check point inhibi-
tors have significantly improved prognosis for patients with various advanced 
malignancies like melanoma, non-small cell lung carcinoma, Hodgkin lymphoma, 
urothelial carcinoma, renal cell carcinoma and head and neck cancer. As medical 
oncology treatments are changing from anatomical sites to molecular sites – immu-
notherapies have established role in certain molecular patterns as well (i.e. MSI 
high, TMB high metastatic tumors).
Immunotherapies include wide array of drugs with different mechanisms 
including monoclonal antibodies, immunomodulators, cytokines, checkpoint 
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inhibitors, chimeric antigen receptor T cell therapy, cancer vaccines and oncolytic 
viruses while many other new approaches are being investigated.
Targeting the immune inhibitory pathways for cancer treatment can lead to 
immunologic self-tolerance imbalance, resulting in immune-related adverse events 
(irAEs) which can virtually affect all the organ systems; including eye and brain 
which are usually unaffected by immune system [2–4]. Different immunotherapies 
usually affect different organs, as Anti-CTLA-4 mAbs are likely to affect colon and 
pituitary gland, while anti-PD-1 (L1) mAbs affect thyroid gland.
Among Anti-CTLA-4 mAbs, Ipilimumab has been approved for melanoma, kidney 
cancer and now NSCLC, and has significantly changed the natural history of advanced 
tumor. Another immunotherapeutic drug tremelimumab is under development. 
Common side effects associated with anti-CTAL-4 mAbs include pruritis, diarrhea, 
rash and fatigue with severe to life-threatening adverse events occurring in less than 5% 
cases. Anti PD-1 and PD-L1 mABs have similar toxicity profile [5]. Nivolumab, pembro-
lizumab, and cemiplimab are anti PD-1 mABs, while atezolizumab, avelumab, and dur-
valumab target PD-L1. In general, anti-PD-1 mAbs are associated with far fewer irAEs 
than Anti-CTLA-4 mAbs. Common side effects associated with Anti PD-1 (L1) mAbs 
fatigue, rash, pruritus and idea with severe to life-threatening adverse events occurring 
in 2–3% of cases. The combination of Anti-CTLA-4 and Anti PD-1 (L-1) antibodies 
have shown better antitumor results but however they have been associated with higher 
incidence of immune therapy related adverse event than monotherapy [6, 7].
Usually these irAEs arise within 3–6 months of starting the immunotherapy but 
it may take few years and thus needs close monitoring for years after completion of 
therapy. These side effects can be graded from mild to moderate as Grade 1–2 and 
severe to life threatening as Grade 3–4 [2, 8].
In general, mild Grade 1 side effects usually requires symptom management and 
does not require immunotherapy discontinuation. Grade 2 or moderate side effects 
usually managed with temporary discontinuation of checkpoint inhibitor. For 
severe to life-threatening Grade 3 and 4 side effects immunotherapy is permanently 
discontinued and these patient usually require high dose of corticosteroids.
Some studies have shown association of irAEs with better antitumor efficacy, 
the data remains conflicting and needs further research confirm whether occur-
rence of irAEs predicts better outcome [9–13].
2. Endocrinological adverse effects of immunotherapy
Immunotherapy can cause wide array of endocrine side effects. More common 
irAEs are hypophysitis leading to hypopituitarism, primary or secondary thyroid 
dysfunction, primary or secondary adrenal insufficiency, autoimmune diabetes 




Hypophysitis is one of the more common immunotherapies induced endocrinopa-
thies and is more common after anti CTLA–4 therapy, reaching around 13% after 
treatment with ipilimumab [14, 15]. Ipilimumab induced hypophysitis (IH) occurs 
more frequently in males and in older age when compared to lymphocytic autoimmune 
hypophysitis even when adjusted for melanoma incidence for age and sex [15–17].
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IH is a type II hypersensitivity reaction in which CTLA-4 antibodies bind to antigen 
expressed on pituitary cells resulting in compliment activation and gland destruction 
[18, 19]. Some studies have suggested that IH development may be associated with 
better antitumor outcomes in terms of morbidity and mortality [14]. The data on 
whether other agents and radiotherapy can alter the risks of hypophysitis is limited.
In the reported studies the average time to IH diagnosis is about 9 weeks; though 
time to endocrine abnormalities development has not been routinely reported in trials.
The radiographic changes seen on MRI including heterogenous pituitary 
enlargement with thickening of stalk are the sensitive and specific indicator of 
hypophysitis and may be the first signs of pituitary dysfunction occurring before 
hormonal disturbances or development of symptoms [1, 20]. The degree of pitu-
itary enlargement can be mild in the patient’s with IH and resolves quickly after 
glucocorticoids treatment [14].
Most common laboratory abnormalities observed at the time of diagnosis 
includes central hypothyroidism with reduction of TSH and secondary adrenal 
insufficiency. Hyponatremia secondary to adrenal insufficiency and hypothyroid-
ism is frequently noted but central diabetes insipidus is rare with IH. Also growth 
hormone or prolactin axis disturbances occur less compared to other hormonal 
deficiencies. Usually, other hormonal deficiencies improved with treatment except 
for adrenal insufficiency which requires lifelong with steroid treatment [14, 21, 22].
3.1.2 Anti-PD-1 and anti PD-L1 mAbs
Multiple studies have shown that incidence of Anti-PD-1 and anti PD-L1 mAbs 
associated hypophysitis is less compared to Anti-CTLA-4 antibodies. Average 
incidence of hypophysitis was 0.6% in patients treated with pembrolizumab and 
novilumab, <0.1% in durvalumab and 0.2% with atezolizumab [23–26].
3.2 Diagnosis and treatment
3.2.1 Monitoring
Patients receiving immunotherapy treatments should have baseline pituitary 
function test done. Routine thyroid function test monitoring with monthly TSH 
and free T4 level checks is recommended during the treatment and when patient 
develops symptoms suggestive of hypophysitis. Those patients who receives anti-
CTLA-4 agents routine monitoring of ACTH and cortisol level should be done.
3.2.2 Diagnosis
A clinician must have high index of suspicion for the hypophysitis diagnosis as 
patient may present with vague symptoms or use of exogenous glucocorticoids may 
mask their presentation so regular monitoring is critical. When suspected, MRI 
should be performed to assess pituitary and rule out other causes of pituitary dys-
function along with hormone profile evaluation including TSH and free T4, ACTH, 
cortisol, LH, FSH, prolactin, estradiol and females and distress return in males. It is 
recommended to investigate for diabetes insipidus only if patient is presenting with 
symptoms such as polyuria or polydipsia.
3.2.3 Treatment
High dose glucocorticoids course is given when hypophysitis is suspected which 
may reverse inflammatory process and prevent the need for longer term hormone 
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replacement in some cases. However, in most patient’s long-term hormonal supple-
mentation for affected hormones is required with thyroid hormone replacement for 
central hypothyroidism or steroid replacement for secondary adrenal insufficiency. 
In premenopausal female estradiol replacement and in men testosterone placement 
should be considered.
4. Thyroid dysfunction
Immunotherapy related thyroid dysfunction can range from painless thyroiditis 
with transient thyrotoxicosis, transient or long-standing hypothyroidism, thyroid 
associated orbitopathy, and occasionally thyroid storm [27–29].
4.1 Incidence
Thyroid disorder can present with nonspecific symptoms such as fatigue and 
weakness. It is important to distinguish between primary versus secondary hypo-
thyroidism, as former is more likely with anti-PD-1 and anti-PD-L1 mAbs with 
incidence ranging from 4–19.5%; and later is more suggestive from hypophysitis 
induced by anti-CTLA-4 mAbs [30].
For patients treated with nivolumab and pembrolizumab, the incidence rates 
of hypothyroidism were similar at 6.5% and 7.9% respectively. Incidence rate for 
hypothyroidism with ipilimumab, nivolumab or pembrolizumab, atezolizumab, 
and the combination of ipilimumab plus nivolumab were 3.8, 7.0, 3.9, and 13.2 
percent, respectively [31].
Primary hyperthyroidism is seen less frequently with immunotherapy with inci-
dence rates for hyperthyroidism with ipilimumab, nivolumab or pembrolizumab, 
atezolizumab, and the combination of ipilimumab plus nivolumab were 1.7, 3.2, 0.6, 
and 8 percent, respectively [31].
4.2 Monitoring
Baseline thyroid function test should be obtained before initiation of immuno-
therapy and after that regular monitoring of thyroid hormone levels including TSH 
and free T4 is recommended before each treatment and also when symptoms arise.
4.3 Diagnosis
High TSH with low free T4 indicates primary hypothyroidism and a low TSH 
and low free T4 indicates hypophysitis. In thyroiditis with transient thyrotoxicosis 
low TSH and high free T4 may be followed by more long-standing hypothyroidism 
high TSH and low free T4.
4.4 Treatment
While asymptomatic patients with mildly elevated TSH level < 10 can be observed, 
thyroid hormone replacement remains the mainstay of treatment in hypothyroidism. 
Dosage adjustment should be done every 4–6 weeks based on TSH level. Patients with 
thyroiditis and transient thyrotoxicosis can be managed symptomatically with beta 
blockers. Immunotherapy can be continued except and case of severe thyrotoxicosis 
when drug might need to be paused until symptoms resolve. Many patients may have 
subclinical hypothyroidism (TSH >20 mIU/L and normal T4) with symptoms, and in 
our experience, this should be treated with close monitoring for clinical improvement.
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5. Primary adrenal insufficiency
5.1 Incidence
The adrenal insufficiency with immunotherapy is rare [32], there have been case 
reports which showed the association of immunotherapies and adrenal insufficiency. 
Data shows that there is a risk of 0.8–1.6% of adrenal insufficiency with ipilimumab 
either as a monotherapy or combination with anti-PDL 1 therapy. There is a 1% risk 
of primary adrenal insufficiency with nivolumab and median time of onset is around 
4.5 months. Data suggests that there is 0.5% risk of primary adrenal insufficiency 
with avelumab and 0.4% risk of adrenal insufficiency in patients with atezolizumab.
There have been reports of subclinical form of adrenalitis with immune check 
point inhibitors, with normal endocrine function but radiographic evidence of 
inflammation of adrenal glands known as adrenalitis-symmetrically enlarged and 
smooth adrenal glands [33].
5.2 Characteristic findings
It is very rare to have primary adrenal insufficiency associated with adrenal 
crisis. Characteristic findings may include weight loss, fatigue, anorexia, nausea, 
vomiting, abdominal pain, orthostatic hypotension, hypoglycemia, eosinophilia, 
hyperpigmentation, hyponatremia, hyperkalemia or hypercalcemia.
5.3 Diagnosis
Low or suppressed morning serum cortisol with high ACTH levels will be seen 
in patients with adrenal insufficiency.
5.4 Treatment
Adrenal crisis is one of the most serious and life-threatening endocrinological 
side effect of immunotherapy, which requires prompt diagnosis and treatment. If 
there is high clinical suspicion of adrenal crisis, after obtaining serum cortisol and 
ACTH levels, treatment should be started without waiting for the results to come 
back. Patients should be given stress doses of steroids, IV hydrocortisone 100 mg 
every six to eight hours and aggressive fluid resuscitation should be made as there 
is high risk of hypovolemic shock. Endocrinologist consult is highly recommended 
as well.
6. Type 1 diabetes mellitus
6.1 Incidence
Type 1 diabetes mellitus is also a rare a side effect in patients treated with 
immunotherapy. Type 1 DM has been observed in around 1% of patients treated 
with nivolumab and in 0.2% of patients treated with pembrolizumab. The median 
time of onset from starting immunotherapy is around 4.5 months.
6.2 Diagnosis
Type 1 DM is rare but when present, ketoacidosis must be investigated and 
treated [34]. Anti-GAD65 can be performed to look for autoimmunity.
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6.3 Mechanism
The most likely mechanism of developing insulin dependent diabetes mellitus is 
inappropriate activation of T cells which cause destruction of pancreatic islet cells [35].
6.4 Treatment
Patients with immune mediated type 1 diabetes mellitus should be referred to 
endocrinology and treated with basal-bolus insulin regimen.
7. Conclusion
With the widespread use of immunotherapies in cancer, the incidence of side 
effects of immune check point inhibitors is also increasing. Physicians should be 
aware of different immune related adverse events (irAE).
Hypophysitis and thyroid dysfunction are the most common endocrinological 
side effects of immune check point inhibitors. Patients who receive anti-CTLA-4 
therapy, the pituitary hormones should be regularly monitored and if there is 
concern for central adrenal or thyroid dysfunction, treatment should be instituted 
as soon as possible, and immunotherapy should be held.
Primary thyroid dysfunction is more common in patients who receive anti-
PD1 and anti-PD-L1 antibodies. Patients may develop hyper or hypothyroidism. 
Hyperthyroidism is mainly transient, which can lead to hypothyroidism requiring 
life-long thyroid hormone treatment.
Most of the endocrine side effects of immune check point inhibitors can be 
adequately treated, clinicians should regularly monitor hormone levels so that it can 
be promptly diagnosed and treated. In patients with mild to moderate endocrinopa-
thies, immunotherapy can be continued with careful monitoring.
Physicians should be aware that irAEs can occur during and after the treatment 
with immunotherapies and a multidisciplinary approach should be used in manag-
ing it. Patient’s education is also very important, and physicians should guide them 
about the symptoms and signs to look for and notify the physicians.
© 2021 The Author(s). Licensee IntechOpen. This chapter is distributed under the terms 
of the Creative Commons Attribution License (http://creativecommons.org/licenses/
by/3.0), which permits unrestricted use, distribution, and reproduction in any medium, 
provided the original work is properly cited. 
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